Delving into the Latest Updates on Multipeptide vaccine(German Consortium For Translational Cancer Research) with Synapse

Overview

Basic Info

Drug Type

Personalized antigen vaccine, Synthetic peptide vaccine

Synonyms-

Target-

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Renal Cell Carcinoma

Inactive Indication-

Originator Organization

German Consortium For Translational Cancer Research

Active Organization

German Consortium For Translational Cancer ResearchUniversitaetsklinikum Tuebingen

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Newly diagnosed HLA-A2-positive MGMT-methylated glioblastoma patients will be vaccinated with a Multi peptide vaccination with Pam3Cys-GDPKHPKSF (XS15) as an immunomodulator in addition to standard postoperative radiation therapy and temozolomide chemotherapy to assess immunogenicity, efficacy, safety of the combination of multipeptide vaccination and the immune modulator XS15 emulsified in Montanide ISA 51 VG

Start Date03 May 2021

Sponsor / Collaborator

University Hospital Tübingen

NCT04688385 / Active, not recruitingPhase 1IIT

iVAC-XS15-CLL01: Personalized Multi-peptide Vaccination in Combination With the TLR1/2 Ligand XS15 in CLL Patients Undergoing Ibrutinib-based Regimes

The aim of this study is to evaluate the efficiency along with safety and toxicity of a personalizied multi-peptide vaccine in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes.

Start Date23 Dec 2020

Sponsor / Collaborator

University Hospital Tübingen

100 Clinical Results associated with Multipeptide vaccine(German Consortium For Translational Cancer Research)

Login to view more data

100 Translational Medicine associated with Multipeptide vaccine(German Consortium For Translational Cancer Research)

Login to view more data

100 Patents (Medical) associated with Multipeptide vaccine(German Consortium For Translational Cancer Research)

Login to view more data

45

Literatures (Medical) associated with Multipeptide vaccine(German Consortium For Translational Cancer Research)

01 Feb 2023·International Journal of Urology

Editorial Comment to Phase I/II study of multipeptide cancer vaccine IMA901 after single‐dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long‐term follow up

Article

Author: Obara, Wataru ; Kato, Renpei

01 Feb 2023·International Journal of Urology

Phase I/II study of multipeptide cancer vaccine IMA901 after single‐dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long‐term follow up

Article

Author: Tamada, Satoshi ; Hongo, Fumiya ; Miki, Tsuneharu ; Ukimura, Osamu ; Nakatani, Tatsuya ; Ueda, Takashi ; Takaha, Natsuki

AbstractBackgroundIMA901 is the first therapeutic vaccine for renal cell cancer (RCC). It contains multiple tumor‐associated peptides (TUMAPs) that are naturally present in human cancers.MethodsIn a phase I/II study, we treated a total of 10 Japanese patients with advanced RCC who were human leukocyte antigen A (HLA‐A)*02 +. Vaccination involved i.d. injection of GM‐CSF (75 μg), followed within 15–30 min by i.d. injection of IMA901 (containing 413 μg of each peptide). No treatment with either anticancer agents or immunosuppressants was allowed within 4 weeks before entering the trial. Patients were scheduled to receive 7 vaccinations during the first 5 weeks of treatment (induction period), followed by 10 further vaccinations at 3‐week intervals for up to 30 weeks (maintenance period). The primary endpoints were safety and tolerability, while the secondary endpoints were PFS, OS, and immunogenicity.ResultsThere were no treatment‐related serious adverse events or deaths during the study period. When the response was assessed after 4 months, 10% of patients showed a partial response, 80% had stable disease, and 10% had progressive disease. Among patients in whom the T‐cell response was analyzed, five patients showed a vaccine‐induced T‐cell response against at least one HLA class I‐restricted TUMAP and two patients had T‐cell responses to multiple TUMAPs. PFS was 5.5 months and OS was 18 months.ConclusionsThis study demonstrated the safety and tolerability of IMA901 vaccine in Japanese RCC patients, and also showed that vaccination elicited an immune response.

01 Aug 2021·Cancer Immunology, ImmunotherapyQ2 · MEDICINE

Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials

Q2 · MEDICINE

Article

Author: Deacon, Donna H ; Koeppel, Alexander F ; Slingluff, Craig L ; Meneveau, Max O ; Turner, Stephen D ; Pollack, Karlyn E ; Petroni, Gina R ; Hickman, Alexandra ; Melssen, Marit M ; Sol-Church, Katia ; Smolkin, Mark E ; Pinczewski, Joel

The strength and durability of systemic anti-tumor immune responses induced by cancer vaccines depends on adjuvants to support an immunogenic vaccine site microenvironment (VSME). Adjuvants include water-in-oil emulsions with incomplete Freund's adjuvant (IFA) and combinations of toll-like receptor (TLR) agonists, including a preparation containing TLR4 and TLR9 agonists with QS-21 (AS15). IFA-containing vaccines can promote immune cell accumulation at the VSME, whereas effects of AS15 are largely unexplored. Therefore, we assessed innate and adaptive immune cell accumulation and gene expression at the VSME after vaccination with AS15 and compared to effects with IFA. We hypothesized that AS15 would promote less accumulation of innate and adaptive immune cells at the VSME than IFA vaccines. In two clinical trials, patients with resected high-risk melanoma received either a multipeptide vaccine with IFA or a recombinant MAGE-A3 protein vaccine with AS15. Vaccine site biopsies were obtained after one or multiple vaccines. T cells accumulated early after vaccines with AS15, but this was not durable or of the same magnitude as vaccination in IFA. Vaccines with AS15 increased durable expression of DC- and T cell-related genes, as well as PD-L1 and IDO1, suggesting complex activation and regulation of innate and adaptive immune function with AS15. These changes were generally greater with vaccines containing IFA, but IFA induced reduction in myeloid suppressor cells markers. Evidence of tertiary lymphoid structure (TLS) formation was observed with both adjuvants. Our findings highlight adjuvant-dependent changes in immune features at the VSME that may impact systemic immune responses.

100 Deals associated with Multipeptide vaccine(German Consortium For Translational Cancer Research)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Renal Cell Carcinoma	Phase 2	-	German Consortium For Translational Cancer Research	-
Renal Cell Carcinoma	Phase 2	-	Universitaetsklinikum Tuebingen	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2009	Phase 2	stage IIB melanoma	121	GM-CSF with multipeptide vaccine	mxyvynwlps(wznldkaypp) = ihufomyqsw isyvkbgfyc (opwqhyeejy ) View more	-	20 May 2009
				Multipeptide vaccine without GM-CSF	mxyvynwlps(wznldkaypp) = hzkdggnitk isyvkbgfyc (opwqhyeejy ) View more